Inactive Instrument

News OXIS International, Inc. Other OTC

Equities

US6918294025

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 26	AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01	MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	Feb. 01	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	Dec. 07	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	Dec. 06	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	CI
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	Nov. 07	AQ
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	Nov. 06	AQ
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06	CI
GT Biopharma Reports Third Quarter 2023 Financial Results	Nov. 01	AQ
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	23-08-22	PU
GT Biopharma Reports Second Quarter 2023 Financial Results	23-08-07	AQ
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023	23-08-03	AQ
GT Biopharma : Submission of Matters to a Vote of Security Holders - Form 8-K	23-07-05	PU
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23-06-23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index	23-06-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OXIS International, Inc. Other OTC

Equities

US6918294025

Summary

Filters